Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

200 Technology Square
Cambridge, MA

Tel: 617-714-6500

Visit website

Email Us

Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. Our workforce has grown significantly over the last few years as we have rapidly scaled to become a global commercial company. With more than 5,500 people around the world, we are focused on creating an environment that is rooted in a strong sense of belonging. Hear from our changemakers.

Every Role Matters, Enabling Transformative Mission

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.

Read Keke’s Story

Take your moment with benefits

We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.

Learn More

NEWS

FDA

CDC Advisors Unanimous on Another COVID-19 Vaccine Option for Kids 6-17

Thursday, a committee of advisors for the CDC voted unanimously for children and teens, ages six to 17 to receive Moderna’s COVID-19 vaccine.

June 20, 2022

3 min read

Hayley Shasteen & Geoff Herman

Drug Development

FDA Authorizes Pfizer-BioNTech, Moderna COVID Vaccines for Children 6 Months to 4 Years

Friday morning, the FDA granted Emergency Use Authorization to both Moderna’s and Pfizer-BioNTech’s COVID-19 vaccines for use in children ages 6 months to 4 years old.

June 17, 2022

3 min read

Alex Keown

Drug Development

Moderna Plans Trial Testing COVID-19 Vaccine in Youngest Babies

Moderna’s study, dubbed BabyCove, is expected to begin recruiting in September and will include up to 700 babies three to six months of age.

June 16, 2022

3 min read

Mark Terry

Policy

FDA Panel Unanimously Recommends Pfizer-BioNTech and Moderna Vaccines for Young Kids

An FDA advisory committee voted Wednesday to recommend both the Pfizer-BioNTech and Moderna COVID-19 vaccines for children as young as six months old.

June 15, 2022

3 min read

Mark Terry

Policy

UPDATE: In Unanimous Vote, FDA Advisory Committee Recommends Moderna’s COVID Vaccine for Kids 6-17

In a unanimous vote, a panel of FDA advisors voted to recommend the approval of Moderna’s COVID-19 vaccine for children between the ages of six and 17 years old.

June 14, 2022

2 min read

Alex Keown

Drug Development

The Race is On as Sanofi-GSK Booster Bests Pfizer-BioNTech

While a handful of companies have dominated the COVID-19 vaccine market in the U.S. and Europe, a number of biotechs are continuing to develop vaccines to use as booster shots.

June 13, 2022

4 min read

Mark Terry

Monkeypox new disease dangerous over the world. Patient with Monkey Pox. Painful rash, red spots blisters on the hand. Close up rash, human hands with Health problem. Banner, copy space. Painful rash, red spots blisters on the hand. Close up Allergy rash, human hands with dermatitis and Health problem. Ill eczema skin of patient. Viral Diseases. Red rashes on the palm. Enterovirus. coxsackie

Policy

US Orders 500K Doses of Bavarian Nordic Monkeypox Vaccine

Bavarian Nordic announced the U.S. Biomedical Advanced Research and Development Authority has ordered an additional 500,000 doses of its monkeypox vaccine, Jynneos.

June 10, 2022

2 min read

Hayley Shasteen

Drug Development

Clinical Catch-Up: Moderna, BioNTech, Eli Lilly & More Tout Positive Data

It was an extraordinarily busy week for clinical trial news and updates due to several prominent international conferences. Here’s a look at some of the highlights.

June 10, 2022

5 min read

Mark Terry